Department of TCM Gynecology, Tongxiang Maternal and Child Health-Care Center, Tongxiang, Zhejiang 314500, China.
Department of Gynecology, Tongxiang Maternal and Child Health-Care Center, Tongxiang, Zhejiang 314500, China.
Complement Ther Med. 2022 Oct;69:102848. doi: 10.1016/j.ctim.2022.102848. Epub 2022 Jun 30.
Shenghua Decoction (SHD) is a well-known classic herbal formula documented in traditional Chinese medicine (TCM) that has been widely applied during the postpartum period in Chinese communities for several years. We conducted this systematic review and meta-analysis to explore the influence of SHD as an adjuvant treatment for early medical abortion using a combination of mifepristone followed by misoprostol.
This systematic review and meta-analysis was reported using 2020 PRISMA guidelines. Eight databases were searched from their establishment to February 28, 2022, for randomized controlled trials (RCTs): PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, the Chinese BioMedical database, the Chinese Scientific Journal Database, and the Wanfang database. The Grading of Recommendations Assessment, Development, and Evaluation estimated the quality of evidence.
Sixteen RCTs involving 3016 patients were included in the meta-analysis. Overall, compared with no treatment as the control group after early medical abortion, patients treated with SHD were associated with a higher complete abortion rate (RR: 1.14; 95% CI: 1.10 - 1.18; P < 0.01, I = 26%, moderate quality), lower incomplete abortion rate (RR: 0.31; 95% CI: 0.24 - 0.41; P < 0.01, I = 0%, moderate quality), and lower viable pregnancy rate (RR: 0.26; 95% CI: 0.11 - 0.62; P < 0.01, I = 0%, moderate quality). Additionally, SHD supplementation was associated with reduced the induction-abortion time, duration of vaginal bleeding and menstrual recovery time.
Our findings suggest that SHD supplementation may be beneficial for women seeking a medical abortion before the 7-week gestational period and no adverse events in the experimental group were reported. However, the methodological quality of the included RCTs was unsatisfactory, and therefore it is necessary to further verify the effectiveness of SHD using standardized studies of rigorous design.
生化汤(SHD)是一种著名的经典中药方剂,在中国社区产后多年来一直被广泛应用。我们进行了这项系统评价和荟萃分析,以探讨 SHD 作为米非司酮联合米索前列醇辅助早期药物流产的影响。
本系统评价和荟萃分析按照 2020 年 PRISMA 指南进行报告。从建立到 2022 年 2 月 28 日,我们在 8 个数据库中搜索了随机对照试验(RCT):PubMed、Embase、Cochrane 图书馆、Web of Science、中国国家知识基础设施、中国生物医学数据库、中国科学期刊数据库和万方数据库。推荐评估、发展和评估分级(Grading of Recommendations Assessment, Development, and Evaluation)评估证据质量。
纳入了 16 项涉及 3016 名患者的 RCT 进行荟萃分析。总体而言,与早期药物流产后不治疗作为对照组相比,接受 SHD 治疗的患者完全流产率更高(RR:1.14;95%CI:1.10-1.18;P<0.01,I = 26%,中等质量),不完全流产率更低(RR:0.31;95%CI:0.24-0.41;P<0.01,I = 0%,中等质量),活胎妊娠率更低(RR:0.26;95%CI:0.11-0.62;P<0.01,I = 0%,中等质量)。此外,SHD 补充剂与缩短诱导流产时间、阴道出血持续时间和月经恢复时间有关。
我们的研究结果表明,SHD 补充剂可能对寻求在 7 周妊娠前进行药物流产的女性有益,且实验组未报告不良事件。然而,纳入的 RCT 方法学质量不理想,因此有必要使用严格设计的标准化研究进一步验证 SHD 的有效性。